Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

ecancer
G

Tremelimumab and Durvalumab as 1L in Unresectable HCC: Phase 3 HIMALAYA Trial

By ecancer FEATURING Ghassan Abou-Alfa
By ecancer FEATURING Ghassan Abou-Alfa
247 views
April 13, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Gastrointestinal
04:39
Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Insights: "PROOF 301 Trial - Oral FGFR Inhibitor …

Feat. G. Abou-Alfa
06:31
ecancer

CheckMate 649 Trial Biomarker Analyses of Nivo + Ipi vs. Chemo for P…

Feat. Y. Y. Janjigian
31:25
Total Health

Updates in Rectal Cancer: Optimizing Response, Preserving the Organ,…

Feat. J. Smith
10:36
CE Concepts

Pathophysiologic Foundations in HCC/BTC: Immune System as a Therapeu…

Feat. J. Harding
11:02
ASCO GI 2023 Conference Coverage

ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. C…

Feat. Y. Y. Janjigian
07:43
ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA for Response Assessment in Patients With Anal Can…

Feat. J. Alvarez
06:16
ASCO GI 2023 Conference Coverage

ASCO GI 2023 on Organ Preservation and Total Neoadjuvant Therapy for…

Feat. P. Romesser
38:04
Debbie's Dream Foundation

Advances in IO and Targeted Agents in Gastroesophageal Cancer

Feat. D. Ilson
05:41
ecancer

An Overview of Treatment Advances in Gastric Cancer

Feat. D. Ilson
04:07
ecancer

ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment i…

Feat. A. Cercek
09:42
ASCO 2022 Conference Coverage

ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Ca…

Feat. J. Harding
58
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advance…

Feat. J. Harding
06:42
ASCO 2022 Conference Coverage

ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabin…

Feat. G. Abou-Alfa
23
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updates on Infigratinib vs. Gemcitabine …

Feat. G. Abou-Alfa
07:48
ecancer

Tremelimumab and Durvalumab as 1L in Unresectable HCC: Phase 3 HIMAL…

Feat. G. Abou-Alfa
20:26
Collaborative Group of the Americas for Inherited Gastrointestinal Cancers

Incidental Findings From Somatic Testing and Implications for Heredi…

Feat. Z. Stadler
08:15
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity…

Feat. R. Sugarman
05:49
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Stu…

Feat. Y. Y. Janjigian
09:30
Memorial Sloan Kettering Cancer Center

ESMO 2021 Update on Nivo + Chemo or Ipi vs. Chemo as 1L Treatment in…

Feat. Y. Y. Janjigian
07:44
Memorial Sloan Kettering Cancer Center

ESMO 2021 Abstract Review on Genomic Landscape of Late-Stage Gastric…

Feat. Y. Y. Janjigian
16:43
Debbie's Dream Foundation

Gastric Cancer: Advances in Systemic Therapy

Feat. D. Ilson
07:10
2021 ASCO Virtual Direct™ Highlights

2021 ASCO CRC Updates: 1L Pembro vs. Chemo, Maintenance Chemo, 2L an…

Feat. L. Connell
09:50
Memorial Sloan Kettering Cancer Center

1L Treatment Updates for Advanced GE/GEJ Cancers: OS Data for Nivo+I…

Feat. Y. Janjigian
21:21
Memorial Sloan Kettering Cancer Center

Frontline Management of Advanced GEJ Cancers: Will 5FU/Oxaliplatin +…

Feat. Y. Y. Janjigian
11:00
Memorial Sloan Kettering Cancer Center

BRAF Alterations in Advanced CRC: How Common Are V600E Mutations? Ho…

Feat. R. Yaeger
17:05
Memorial Sloan Kettering Cancer Center

Liver-Directed Therapy for mCRC: What Is the Goal, When to Use and H…

Feat. A. Cercek
13:27
2020 Virtual ESMO Review

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoi…

Feat. L. Connell
08:07
2020 Virtual ESMO Review

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the Qoli…

Feat. L. Connell
11:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Locoregional CRC: 3 vs. 6 Months of Adjuvant Oxa…

Feat. L. Connell
09:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New So…

Feat. L. Connell
14:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafen…

Feat. L. Connell
22:02
Memorial Sloan Kettering Cancer Center

The Role of Modern RT Techniques in Management of Esophagogastric Ca…

Feat. A. Wu
18:32
Memorial Sloan Kettering Cancer Center

Advanced Surgical Techniques for Early Stage Esophagogastric Cancer:…

Feat. D. Molena
20:17
Memorial Sloan Kettering Cancer Center

Current and Future Personalized Systemic Targets in Esophagogastric …

Feat. G. Ku